BETA-2
Clinical safety rating
cautionComprehensive clinical and safety monograph for BETA-2 (BETA-2).
Comprehensive clinical and safety monograph for BETA-2 (BETA-2).
FDA-approved: Treatment of asthma (acute bronchospasm and prophylaxis), COPD exacerbationsOff-label: Preterm labor tocolysis, hyperkalemia
Beta-2 adrenergic receptor agonist; stimulates adenylate cyclase, increasing cAMP, leading to bronchodilation and inhibition of mast cell mediator release.
| Metabolism | Metabolized by catechol-O-methyltransferase (COMT), monoamine oxidase (MAO), and sulfate conjugation in the gastrointestinal tract and liver. |
| Excretion | Primarily renal excretion of unchanged drug and sulfate conjugates; 60-70% as unchanged drug, 15-20% as sulfate metabolites, minor biliary/fecal elimination (<5%). |
| Half-life | Terminal elimination half-life of 3-6 hours; clinical context: requires frequent dosing (every 4-6 hours) for sustained bronchodilation. |
| Protein binding | 50-60% bound to albumin. |
| Volume of Distribution | 4-5 L/kg (large Vd indicating extensive tissue distribution, particularly lung tissue). |
| Bioavailability | Inhalation: 10-20% (due to deposition and first-pass metabolism from swallowed portion). Oral: 40-50% (significant first-pass metabolism to sulfate conjugates). |
| Onset of Action | Inhalation: 5-15 minutes (short-acting beta-agonist). Oral: 30-60 minutes. |
| Duration of Action | Inhalation: 3-6 hours. Oral: 4-8 hours. Clinical note: short-acting, used for acute symptom relief, not maintenance therapy. |
| Molecular Weight | 239.31 |
2.5 mg via nebulization every 4-6 hours as needed for bronchospasm; or 90 mcg (2 inhalations) via metered-dose inhaler every 4-6 hours.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min; for GFR <30 mL/min, reduce dose by 50% and monitor for systemic effects. |
| Liver impairment | No specific Child-Pugh-based adjustments; caution in severe hepatic impairment due to reduced clearance; consider dose reduction of 50% in Child-Pugh Class C. |
| Pediatric use | 0.15 mg/kg/dose (max 5 mg) via nebulization every 4-6 hours; or 1-2 inhalations (90 mcg each) via MDI every 4-6 hours as needed. |
| Geriatric use | Use lowest effective dose; potential for increased cardiovascular sensitivity; consider starting at 1.25 mg nebulization or 1 inhalation every 6 hours, titrate cautiously. |
| 1st trimester | Limited human data; avoid use unless potential benefit outweighs risk. Beta-agonists have been associated with gastroschisis in some studies, but risk appears low. |
| 2nd trimester | Use with caution; may cause maternal tachycardia and hyperglycemia. Potential for preterm labor inhibition but not established as safe. |
| 3rd trimester | Avoid near term due to risk of neonatal hypoglycemia, bradycardia, and respiratory depression. May inhibit uterine contractions and delay labor. |
Clinical note
Comprehensive clinical and safety monograph for BETA-2 (BETA-2).
| Placental transfer | Crosses placenta via passive diffusion; fetal serum concentrations are approximately 50% of maternal levels. |
| Breastfeeding | Excreted into breast milk in low concentrations; unlikely to cause adverse effects in the infant. Monitor infant for signs of beta-adrenergic stimulation (tachycardia, jitteriness). |
| Lactation Rating | L2 (Safe, but limited data) |
| Teratogenic Risk | FDA Pregnancy Category C. First trimester: Insufficient human data; animal studies show teratogenicity at high doses. Second/third trimester: Risk of fetal tachycardia, hypoglycemia, and intrauterine growth restriction due to beta-2 receptor stimulation. Prolonged use may delay labor. |
| Fetal Monitoring | Maternal: Heart rate, blood pressure, serum potassium, blood glucose, and signs of pulmonary edema. Fetal: Heart rate patterns, growth ultrasound, and biophysical profile if used for tocolysis. |
| Fertility Effects | No known adverse effects on fertility in humans; animal studies show no impairment at therapeutic doses. May cause reversible menstrual irregularities at high doses. |
■ FDA Black Box Warning
Increased risk of asthma-related death with beta-2 agonists; use inhaled beta-2 agonists alone for asthma is not recommended without concomitant inhaled corticosteroid.
| Serious Effects |
Hypersensitivity to beta-2 agonistsCardiac arrhythmias (e.g., tachyarrhythmias)
| Precautions | Paradoxical bronchospasm, cardiovascular effects (tachycardia, hypertension, arrhythmias), hypokalemia, hyperglycemia, immediate hypersensitivity reactions, and worsening of asthma symptoms. |
| Food/Dietary | No significant food interactions. Avoid caffeine-containing foods and beverages if experiencing palpitations or tremors. Maintain adequate potassium intake as beta-2 agonists can cause hypokalemia. |
| Clinical Pearls | Beta-2 agonists (e.g., albuterol, salmeterol) are primarily used for bronchodilation in asthma and COPD. Short-acting beta-2 agonists (SABAs) are first-line for acute symptoms, while long-acting beta-2 agonists (LABAs) are maintenance therapy, never as monotherapy in asthma. Monitor for hypokalemia and tachycardia. Use with caution in patients with cardiovascular disease, hyperthyroidism, or diabetes. Inhaled route minimizes systemic effects. Overuse indicates poor disease control. |
| Patient Advice | Use only as prescribed; do not increase frequency or dose without consulting your doctor. · Rinse mouth with water after using inhalers containing corticosteroids to prevent thrush. · Seek emergency help if symptoms worsen or if you need more than 2 puffs per week of rescue inhaler. · Know the difference between rescue (blue) and controller (usually brown/purple) inhalers. · Shake inhaler well before use and use proper technique (spacer if needed). · Report palpitations, chest pain, or severe anxiety to your healthcare provider. · Do not stop controller medication suddenly as it may cause worsening of symptoms. |
Loading safety data…